NASDAQ: APREAprea Therapeutics Inc Stock
$1.65+0.05 (+3.13%)
Updated Aug 22, 2025
APRE Price
$1.65
Fair Value Price
N/A
Market Cap
$9.58M
52 Week Low
$1.41
52 Week High
$5.01
P/E
-0.72x
P/B
0.71x
P/S
12.22x
PEG
N/A
Dividend Yield
N/A
Revenue
$841.01k
Earnings
-$13.85M
Gross Margin
100%
Operating Margin
-1,766.47%
Profit Margin
-1,646.8%
Debt to Equity
0.29
Operating Cash Flow
-$13M
Beta
0.59
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
APRE Overview
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine APRE's potential to beat the market
- APRE doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
APRE
RankedUnranked of 484
RankedUnranked of 484
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.91 | A | |
| $41.50 | A | |
| $12.27 | A |
Be the first to know about important APRE news, forecast changes, insider trades & much more!
APRE News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how APRE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
APRE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
APRE is good value based on its book value relative to its share price (0.71x), compared to the US Biotechnology industry average (4.61x)
P/B vs Industry Valuation
APRE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more APRE due diligence checks available for Premium users.
Valuation
APRE fair value
Fair Value of APRE stock based on Discounted Cash Flow (DCF)
Price
$1.65
Fair Value
$5.35
Undervalued by
69.15%
APRE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
APRE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.72x
Industry
-111.74x
Market
35.55x
APRE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.71x
Industry
4.61x
APRE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
APRE's financial health
Profit margin
Revenue
$118.1k
Net Income
-$3.2M
Profit Margin
-2,742.2%
APRE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
APRE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$17.3M
Liabilities
$3.9M
Debt to equity
0.29
APRE's short-term assets ($16.93M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APRE's short-term assets ($16.93M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APRE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
APRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.1M
Investing
$0.0
Financing
$384.9k
APRE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
APRE vs Biotech Stocks
Aprea Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.